Financings Roundup

October 2007
BioWorld Today;10/10/2007, Vol. 18 Issue 197, p6
The article reports on the plan by Genoptix Inc. of Carlsbad, California to launch an initial public offering (IPO). The company has set a price range of $14 to $16 per share for its proposed IPO, which will include 5 million shares and an additional 750,000 shares to cover any overallotments. Genoptix said it expects to generate net proceeds of $57.7 million from the offering.


Related Articles

  • Financings Roundup.  // BioWorld Today;11/6/2007, Vol. 18 Issue 216, p7 

    The article reports that Genoptix Inc. has closed its initial public offering of 5 million shares. The company says that underwriters exercised in full their 30-day overallotment option of 750,000 shares at the $17 purchase price. Genoptix reported net proceeds of $72.7 million and plans to use...

  • By the numbers.  // njbiz;10/6/2014, Vol. 27 Issue 40, p1 

    The article presents the number of initial public offerings (IPO) through three quarters of 2014 in New Jersey.

  • Genoptix IPO nets $72.7 million; LabCorp in $500M share buyback.  // Diagnostics & Imaging Week;11/8/2007, Vol. 10 Issue 45, p3 

    This article reports that specialized laboratory service provider Genoptix has successfully closed its initial public offering deal. The total shares sold by Genoptix was 4,735,714 and priced at $17 per share. Information regarding the net proceeds from the deal is given. Particular focus is...

  • Nanosphere, Genoptix both price their IPOs at $14 to $16 a share. Johnson, Holland // Medical Device Daily;10/30/2007, Vol. 11 Issue 208, p1 

    The article reports on the initial public offering (IPO) of Nanosphere and Genoptix. Both companies first filed for their respective initial public offerings in August 2007. Both will also be listed on the Nasdaq Global Market. The financial terms of both IPO are presented along with data on...

  • Diagnostic lab Genoptix files for IPO of up to $86.25 million. Morrison, Trista // Medical Device Daily;8/3/2007, Vol. 11 Issue 147, p1 

    The article reports that Genoptix, a provider of specialized laboratory and diagnostic services for community-based hematologists and oncologists, filed to raise $86.25 million in its initial public offering. Genoptix is one of the 12 biotechnology companies that are waiting for approval. The...

  • FINANCINGS ROUNDUP.  // BioWorld Today;2/15/2008, Vol. 19 Issue 32, p6 

    This section presents updates on financial transactions in the U.S. biopharmaceutics sector. Underwriters of Acorda Therapeutics Inc. have exercised their entire option to purchase an additional shares of common stock in association with the company's public offering. A common stock purchase...

  • Financings roundup.  // Medical Device Daily;10/31/2007, Vol. 11 Issue 209, p8 

    The article reports that the 5 million shares of common stock will be sold by Genoptix at $14 per share during its initial public offering. Share price is higher compared to the estimated value made public by the company. A 30-day option to purchase additional shares was granted by Genoptix and...

  • IN THE PIPELINE.  // Investment Dealers' Digest;9/13/2004, Vol. 70 Issue 35, p16 

    This article focuses on the events related to the financial market of the United States that are in the offing. Stonemor Partner is going to bring its Initial Public Offering. Non-IPO list contains the names of Amedisys, Catapult Communications and Wheeling-Pittsburgh.

  • NEW STOCK ISSUES GO UP, UP, UP, AND WALL STREET CRIES: MORE! Norton, Rob // Fortune;10/18/1993, Vol. 128 Issue 9, p27 

    Focuses on the boom in the initial public offerings (IPOs) market in the U.S., as of October 18, 1993. Number of companies that have already registered $6 billion in IPOs with the Securities and Exchange Commission to be issued next year; Reason for market's strength; Diversity of companies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics